Large-Scale, Single Cell Datasets Available for Commercial Licensing

Accelerate your drug discovery programs and power the next generation of AI models with access to some of the largest and most comprehensive single cell datasets available for commercial use. All datasets are generated using Parse’s Evercode combinatorial barcoding technology, enabling unmatched scale and quality. The following datasets are available for commercial use following completion of a license agreement.

Access raw and processed data, complete metadata, and experimental details to fast-track your internal research programs. This supplements your existing internal pipelines and shortens discovery cycles.

What’s Included with a Licensed Dataset

Each dataset license is fully configurable to meet the requirements of your organization. Parse provides a range of deliverables, including raw FASTQ files, processed gene count matrices, metadata, and detailed experimental documentation, and will tailor access to match your analytical pipelines and research objectives. Our team collaborates with you to determine the scope, format, and level of support that advance your research objectives.

Overview of Available Datasets for Commercial Licensing

Below is the current catalog of datasets available for licensing. New large-scale drug perturbation datasets are in progress and will be released soon.

1. 10 million human PBMC screen with 90 cytokine treatments

• PBMCs from 12 human donors (6 male; 6 female) were subjected to 90 cytokine treatments plus PBS control for 24 hours (Figure 1, left).
• Fixed samples were processed in the GigaLab using a Hamilton liquid handler. Libraries were sequenced using the Ultima Genomics sequencing platform and achieved ~31,000 mean reads per cell.
• 9,697,974 cells across 18 immune cell types were identified, including rare populations (Figure 1, right).
• Full details of experimental setup and preliminary findings are on our website.

Inquire about this dataset

2. High-throughput profiling of a cancer cell line drug screen

• Two cancer cell lines: A549 (lung carcinoma) and THP-1 (acute monocytic leukemia) were subjected to 88 histone-modifying drug treatments plus DMSO controls at 2.5 µM for 6, 24, 32, or 48 hours (Figure 2).
• Cells were fixed using the Low Input Fixation workflow, processed through the Evercode WT Mega 384 kit automated using Integra Assist Plus pipetting robot.
• Approximately 20,000 cells per treatment and ~10,000 reads per cell.
• Full details of experimental setup are on our website; data can be explored in Trailmaker.

Figure 2: Experimental design for the high-throughput cancer cell line drug screen.

Inquire about this dataset

3. An anti-diabetic 88-compound, four-timepoint single cell drug screen

• HEK293 and NIH-3T3 cells received 10 µM treatment for 1, 3, 6, or 24 hours.
• The panel of 88 small molecule anti-diabetic drugs covered diverse mechanisms of action, including insulin sensitizers, sulfonylureas, and DPP-4 inhibitors, plus DMSO controls (Figure 3).
• ~20,000 cells per well were fixed using the Low Input Fixation workflow and processed through the Evercode WT Mega 384 kit.
• Full details of experimental setup are on our website; data can be explored in Trailmaker.

Figure 3: Plate layout of the 88-compound anti-diabetic drug screen.

Inquire about this dataset

4. 5 million mouse single nuclei atlas from 7 tissues

• Tissues collected for the atlas included the liver, eye, heart, kidney, colon, quadriceps muscle, and brain, harvested from one male and one female mouse.
• Samples were processed using the Evercode WT Penta kit, and 32 sublibraries sequenced using a NovaSeq X at a sequencing depth of 10,000 reads per cell.
• 5 million nuclei were mapped to 211 distinct cell types, including rare and complex subtypes.
• Full details of experimental setup are on our website; data can be explored in Trailmaker.

Figure 4: UMAP of the 5 million mouse single nuclei atlas.

Dataset Comparison

Inquire about this dataset